Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-10-05Clinical Trial Update: Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder [Phase 3]
Phase 3 trial evaluating adjunctive topiramate for obsessive-compulsive disorder. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2011-09-16Clinical Trial Update: Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD) [NA]
A completed clinical trial evaluated aripiprazole for patients with schizophrenia who also exhibit obsessive-compulsive symptoms.
-
FDA approval · 2011-08-19FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for SERTRALINE HYDROCHLORIDE (Mylan Pharmaceuticals Inc.), indicating regulatory action on this gene…
-
CLINICAL_TRIALS trial_result · 2011-08-08Clinical Trial Update: Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder [Phase 4]
Phase 4 trial comparing conventional-dose versus high-dose escitalopram for clinical improvement in obsessive-compulsive disorder has comple…
-
CLINICAL_TRIALS trial_result · 2011-08-08Clinical Trial Update: Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project [Phase 1, Phase 2]
A completed pilot study evaluating behavioral treatment for obsessive-compulsive symptoms in youth with Prader-Willi syndrome (Phase 1/Phase…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-07-27FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) from Zydus Lifesciences Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2011-07-14Clinical Trial Update: Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)
This update reports the termination of a clinical trial using functional MRI to study gambling disorder and obsessive-compulsive disorder.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Efficacy of Treatment for Obsessive Compulsive Disorder
This clinical trial update reports the efficacy outcomes of a treatment for Obsessive-Compulsive Disorder from a completed study conducted b…
-
FDA approval · 2011-03-16FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for fluvoxamine maleate by ANI Pharmaceuticals, indicating changes to the existing approval (e.g., l…
-
FDA approval · 2011-03-14FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for sertraline hydrochloride from Aurobindo Pharma Limited, enabling its generic product.
-
FDA approval · 2011-03-04FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited.
-
CLINICAL_TRIALS trial_result · 2011-02-24Clinical Trial Update: Ondansetron Augmentation in Treatment-resistant OCD [Phase 4]
A Phase 4 study evaluating ondansetron augmentation in treatment-resistant obsessive-compulsive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2011-02-24Clinical Trial Update: Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) [Phase 4]
Phase 4 trial evaluating ondansetron for treatment-resistant obsessive-compulsive disorder has completed.
-
FDA approval · 2011-01-30FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Paroxetine hydrochloride by Zydus Lifesciences Limited, indicating an update to the labeling or …
-
CLINICAL_TRIALS trial_result · 2011-01-21Clinical Trial Update: Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study [Phase 2]
Phase 2 trial evaluating the addition of quetiapine for obsessive-compulsive disorder has completed.
-
FDA approval · 2010-12-10FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) submitted by NorthStar Rx LLC. This action represents an a…
-
FDA approval · 2010-10-15FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride (generic) from Zydus Lifesciences Limited, authorizing a generic paroxe…
-
FDA label_change · 2010-09-20FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for fluoxetine hydrochloride by PAI Holdings to modify the product labeling.
-
CLINICAL_TRIALS research · 2010-08-30Clinical Trial Update: Cognitive-Behavioral Bibliotherapy for the Treatment of Obsessive Compulsive Disorder in Children and Adolescents [NA]
This clinical trial update reports the completion of a study evaluating cognitive-behavioral bibliotherapy as a treatment for obsessive-comp…
-
CLINICAL_TRIALS trial_result · 2010-08-09Clinical Trial Update: A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder [Phase 3]
Phase 3 trial update indicating completion of a study evaluating daily cognitive-behavioral therapy for pediatric obsessive-compulsive disor…
-
FDA approval · 2010-06-25FDA Approved: FLUOXETINE — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for fluoxetine hydrochloride (fluoxetine) from QUALLENT PHARMACEUTICALS HEALTH LLC, updating the app…
-
FDA approval · 2010-06-21FDA Approved: PAROXETINE HYDROCHLORIDE — Original Application (Oxford Pharmaceuticals, LLC)
FDA approved Paroxetine hydrochloride as an Original Application (ANDA) generic for Oxford Pharmaceuticals, LLC.
-
FDA approval · 2010-05-19FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Apotex Corp)
FDA approves a supplemental application for fluvoxamine maleate from Apotex Corp. This action updates the approval status of the generic pro…
-
FDA approval · 2010-05-19FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for fluoxetine submitted by Teva Pharmaceuticals USA, Inc. (the snippet does not specify the exact c…
-
FDA approval · 2010-03-25FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for paroxetine hydrochloride hemihydrate from Mylan Pharmaceuticals Inc., advancing the generic …